Effect of Feminizing Hormone Therapy on QTc Interval
A Secondary Analysis of a Randomized Clinical Trial

Lachlan M. Angus, MBBS; Tina Lin, MBBS; Shalem Y. Leemaqz, PhD; Ada S. Cheung, PhD

Introduction
The adult QT interval has sex-specific reference ranges, reflecting a decrease in the QT interval by 20 ms after male puberty. The QT interval appears to be modulated by serum testosterone concentrations; it is prolonged in men treated with androgen deprivation therapy for prostate cancer and shortened in women with hyperandrogenism. A 2022 cohort study showed an increased risk of arrhythmia in transgender women compared with cisgender women, but the mechanisms are unclear. We examined the effect of feminizing hormone therapy on the QT interval in transgender women and nonbinary or transfeminine individuals and hypothesized that this would be prolonged due to suppression of serum testosterone levels.

Methods
In this secondary analysis of a randomized clinical trial, we recruited transgender women and nonbinary or transfeminine individuals commencing feminizing hormone therapy as part of a clinical trial examining antiandrogen medications and feminization in 2020 to 2022 (see trial protocol and statistical analysis plan in Supplement 1; Australian New Zealand Clinical Trials Registry Identifier: 12620000339954). Participants provided written informed consent, and approval was obtained from the Austin Health Human Research Ethics Committee. This study followed the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline.

Participants were treated with standardized estradiol therapy and randomized to spironolactone 100 mg daily or cyproterone acetate 12.5 mg daily for 6 months. The QT interval was measured once by a single reader (T.L.) from an electrocardiogram and corrected using the Bazett formula at baseline and 6 months. Serum total testosterone and estradiol concentrations were measured in fasting blood samples via liquid chromatography mass spectrometry. Statistical analysis was performed using R statistical software version 4.3.2 (R Project for Statistical Computing) using additional packages (readxl, nlme, emmeans, pbkrtest, and ggplot2). A linear mixed-effects model was used to measure the effect of treatment on the QT interval corrected for heart rate (QTc) over time, adjusting for age and body mass index (calculated as weight in kilograms divided by height in meters squared). Mean difference and corresponding 95% CIs were estimated from predefined post hoc contrasts. P < .05 was deemed statistically significant.

Results
Of 62 individuals enrolled and randomized, 55 women and nonbinary or transfeminine individuals were included in the per protocol analysis (28 and 27 individuals receiving cyproterone acetate and spironolactone, respectively). At 6 months, the overall mean difference in QTc interval was 19.1 ms (95% CI, 13.0-25.3 ms; P < .001) (Table), with no between-group difference. No QTc intervals measured were greater than 450 ms, and no arrhythmias were observed. However, 26 participants (51.0%) had an increase in QTc interval greater than 20 ms, and 2 participants (3.9%) had an increase in QTc interval greater than 60 ms, which may be clinically significant (Figure).

Open Access. This is an open access article distributed under the terms of the CC-BY License.
The median (IQR) serum estradiol concentration increased from 117.0 (92.0-245.5) pmol/L at baseline to 383.0 (266.9-580.5) pmol/L at 6 months, with no between-group difference. The median (IQR) serum total testosterone concentration decreased from 16.6 (12.5-22.3) nmol/L at baseline to 1.0 (0.6-2.8) nmol/L at 6 months and was lower in the cyproterone acetate than spironolactone group (0.8 [0.6-1.0] vs 1.8 [0.8-4.5] nmol/L; \( P = .001 \))

**Discussion**

In this secondary analysis of a randomized clinical trial of transgender women and nonbinary or transfeminine individuals commencing feminizing hormone therapy, there was statistically significant prolongation of the mean QTc interval by 19.1 ms over 6 months. Despite lower serum total testosterone concentrations in individuals treated with cyproterone acetate (due to potent

**Table. Participant Characteristics**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Participant measure, median (IQR) (N = 55)</th>
<th>P valuea</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline  6 mo</td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td>25.3 (21.9-28.7) NA</td>
<td>NA</td>
</tr>
<tr>
<td>Race and ethnicity, No. (%)b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>African or Black</td>
<td>2 (3.6) NA</td>
<td>NA</td>
</tr>
<tr>
<td>Asian</td>
<td>4 (7.3) NA</td>
<td>NA</td>
</tr>
<tr>
<td>White</td>
<td>50 (90.9) NA</td>
<td>NA</td>
</tr>
<tr>
<td>Otherc</td>
<td>2 (3.6) NA</td>
<td>NA</td>
</tr>
<tr>
<td>BMI</td>
<td>26.5 (21.4-30.9) NA</td>
<td>NA</td>
</tr>
<tr>
<td>Serum estradiol, pg/mL</td>
<td>31.8 (25.1-63.9) 104.3 (72.7-158.1)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Serum total testosterone, ng/dL</td>
<td>478.8 (360.5-643.2) 28.8 (17.3-80.8)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Serum potassium, mean (SD), mEq/L</td>
<td>4.0 (0.3) 4.0 (0.3)</td>
<td>.97</td>
</tr>
<tr>
<td>Manual QTc interval, mean (SD), ms</td>
<td>365.2 (23.2) 384.3 (22.1)</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); NA, not applicable; QTc, QT interval corrected for heart rate.

SI conversion factors: To convert estradiol to picomoles per liter, multiply by 3.671; potassium to millimoles per liter, multiply by 1.0; testosterone to nanomoles per liter, multiply by 0.0347.

a \( P < .05 \) was deemed statistically significant.

b Participants self-reported race and ethnicity using a survey instrument from the following options and could select multiple options if applicable: Aboriginal and Torres Strait Islander, African/Black, Asian, Hispanic/Latino, Indian subcontinent, Middle Eastern, Pacific Islander, and White. Race and ethnicity were assessed given that participants were expected to be predominantly White, which may limit generalizability of findings.

c Other includes Aboriginal and Torres Strait Islander and Indian subcontinent, which were combined due to low sample size.

**Figure. Waterfall Plot of QTc Interval Change Over 6 mo by Participant**

![Figure](image-url)
progestogenic effects), there was no between-group difference in the QTc interval. We speculate that QTc interval may be mediated by tissue-level androgen activity rather than serum testosterone concentration given that cyproterone acetate and spironolactone are peripheral androgen receptor antagonists.

Study limitations include the lack of a control group treated with estradiol monotherapy. Additionally, participants were generally young, White, and free of comorbidity, and the QT interval was measured once by a single reader.

Further research is needed to determine the clinical significance of these findings. Our findings would support use of the female reference range for interpretation of the QTc interval in people taking feminizing hormone therapy in the absence of a larger dataset of transgender women and nonbinary or transfeminine individuals.

ARTICLE INFORMATION
Accepted for Publication: January 31, 2024.
Published: March 28, 2024. doi:10.1001/jamanetworkopen.2024.3994
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2024 Angus LM et al. JAMA Network Open.
Corresponding Author: Lachlan M. Angus, MBBS, Trans Health Research, Department of Medicine, University of Melbourne, 145 Studley Rd, Heidelberg VIC 3084, Australia (lachlan.angus@outlook.com).
Author Affiliations: Trans Health Research, Department of Medicine, University of Melbourne, Victoria, Australia (Angus, Cheung); Department of Cardiology, Austin Health, Victoria, Australia (Lin); College of Medicine and Public Health, Flinders University, South Australia, Australia (Leemaqz).
Author Contributions: Dr Angus had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Angus, Cheung.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Angus, Lin, Cheung.
Critical review of the manuscript for important intellectual content: Lin, Leemaqz, Cheung.
Statistical analysis: Leemaqz.
Obtained funding: Cheung.
Administrative, technical, or material support: Angus, Cheung.
Supervision: Lin, Cheung.
Conflict of Interest Disclosures: Dr Angus reported receiving grants from Kyowa Kirin Australia outside the submitted work. Dr Cheung reported receiving products for investigator-initiated trials (estradiol and progesterone) from Besins Healthcare outside the submitted work. No other disclosures were reported.
Funding/Support: Dr Angus was supported by the Research Training Program Scholarship from the Australian Government. Dr Cheung was supported by Australian Government National Health and Medical Research Council Investigator Grant 2008956. This study was funded by the Austin Medical Research Foundation, Endocrine Society of Australia Postdoctoral Award, and Royal Australasian College of Physicians Foundation Cottrell Research Establishment Fellowship Award.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Data Sharing Statement: See Supplement 2.
Additional Contributions: The authors thank James Doery, MD, and Kwok Chung (Gary) Liu, masters of clinical laboratory science/medical technology/technologist (Monash Pathology, Clayton, Victoria), for setting up and overseeing serum sex steroid assays using mass spectrometry for serum total testosterone and estradiol measurements and Jeffrey Zajac, PhD, and Mathis Grossmann, PhD (University of Melbourne, Heidelberg, Victoria), for providing manuscript review and feedback. These individuals were not compensated for this work.
REFERENCES


SUPPLEMENT 1.
Trial Protocol

SUPPLEMENT 2.
Data Sharing Statement